Imipenem - cilastatina versus ceftazidima - amikacina para el tratamiento de pacientes neutropénicos febriles / Imipenem - cilastatine versus ceftazidime - amikacin in the treatment of febril neutropenic patients
Rev. méd. Chile
;
123(3): 312-20, mar. 1995. tab
Artículo
en Español
| LILACS
| ID: lil-151186
RESUMO
Aim:
To compare the efficacy of imipenem - cilastatine and ceftazidime - amikacin in the treatment of febril neutropenic patients.Design:
Open prospective and randomized clinical study. Patients 52 patients (26 females) aged 16 to 80 years old with 60 episodes of neutropenia were studied. They were randomly assigned to receive Imipenem - cilastatine in doses of 500 mg iv qid or the combination of ceftazidime 1 to 1.5 g iv tid and amikacin 7.5 mg/kg iv bid.Results:
Global response to initial therapy was 53 percent in patients receiving imipenem - cilastatine and 37 percent in those receiving ceftazidime - amikacin (p=ns). When other antimicrobial were added, a 90 and 85 percent infection eradication success was achieved respectively. Six febrile episodes in the group receiving imipenem - cilastatine and 12 episodes in tha group receiving ceftazidime - amikacin had Gram positive cocci as the sole treatment outcome. Three patients receiving imipenem - cilastatine (10 percent) and 4 receiving ceftazidime - amikacin (13 percent) died. Superinfections and toxicity related to antibiotics were minimal in both groups.Conclusions:
imipenem - cilastatine and the combination of ceftazidime with amikacin were equally effective in the treatment of febril episodes in neutropenic patients
Buscar en Google
Índice:
LILACS (Américas)
Asunto principal:
Amicacina
/
Cilastatina
/
Ceftazidima
/
Imipenem
/
Neutropenia
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio de etiología
/
Guía de Práctica Clínica
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
1995
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS